Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Royalty Pharma's Marketable Securities for the quarter that ended in Jun. 2026 was MXN15,956 Mil.
Royalty Pharma's annual Marketable Securities
increased
from Dec. 2023 (MXN12,845 Mil) to Dec. 2024 (MXN17,560 Mil) but then
declined
from Dec. 2024 (MXN17,560 Mil) to Dec. 2025 (MXN15,722 Mil).
Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".
Royalty Pharma Marketable Securities Related Terms
Royalty Pharma Marketable Securities Historical Data
* Premium members only.
The historical data trend for Royalty Pharma's Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Marketable Securities of MXN15,956 Mil mean?
Royalty Pharma (MEX:RPRXN) has a Marketable Securities of MXN15,956 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Marketable Securities too high?
Royalty Pharma's current Marketable Securities is MXN15,956 Mil. Overall, Royalty Pharma has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Marketable Securities compare to ROIV and INCY?
Royalty Pharma's Marketable Securities of MXN15,956 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Marketable Securities is MXN15,956 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (MEX:RPRXN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN559.33, compared to a current price of MXN1,025.44 — trading 83.3% above its estimated fair value. The current Marketable Securities is MXN15,956 Mil. Royalty Pharma's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Royalty Pharma (MEX:RPRXN), the current Marketable Securities is MXN15,956 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (MEX:RPRXN) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of MXN1,025.44 is trading 83.3% above its estimated GF Value™ of MXN559.33.
GuruFocus considers Royalty Pharma to be Significantly Overvalued.
Key valuation signals for MEX:RPRXN:
Marketable Securities: MXN15,956 Mil
GF Value™: MXN559.33 vs. price of MXN1,025.44 (83.3% above fair value)
No single metric tells the full story. See the MEX:RPRXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
65GF Score
Get the complete analysis for MEX:RPRXN
Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RPRXN has been successfully added to your 
